The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Indeed Bob - SCLP is going to be bought out for a pittance the instant Redmile go over 30 percent (obviously imminent several months ago), then they're going to delist, then there's no interest from anyone for anything, but meanwhile recruitment to the trials progresses well, and a target ORR of 70 percent (ambitiously beyond the industry standard) is comfortably exceeded. Some people seem to forget how rigorous and thorough trials are, and how the issuing of updates every two minutes would probably be a bad sign. Prolonged silence means work is progressing imo. Patience is a virtue, but the exit door is always available to those who want out.
In the absence of news, its amazing what theories people come up with to fill the void 😆
Stop trying to second guess whats going on. Its all positive and the research is progressing nicely. Forget big pharmas and let the research speak for itself.
Ultimately, there are real people whose lives are being directly impacted by what SCLP are doing, so let's focus on the big picture.
The weather must be gloomy in Transylvania 😒
With all the Conferences/Presentations that Sclp have attended. I'm beginning to feel that big Pharmas are saying Oh no Not Sclp again. Look at the SP reaction similar every time after. It's beginning to look like their flogging a dead horse. If Pharmas were Impressed with Sclp the SP would be higher and there would be a buzz about. The only reason to attend Is to try and attract a customer, why else If they already Have Interest. IF something positive Is not presented In the next couple of months the SP will head towards 5P. Then again maybe It's because there's a 100BL price tag IMO
Is there any point in trying to pump Scib at these conferences? Its hard to imagine that there are more than a handful of major players who woulð want and can afford to buy it outright from us, it would be easier and just as effective to just to courier the latest data staight onto the desk of the CEOs ... if the data continues to impress the value simply increases and the pool of prospective buyers shrinks even further. My sense is that these conference junkets are ideal for one to one conversations but the actual presentations are pretty much a waste of time. I refuse to get excited about presentations any more, nothing much will change here until a large amount of cash arrives hopefully big enough to move the share price permanently . Unless of course, a Nasdaq listing is much closer than we imagine...in which case presenting to a knowledgable US audience may be valuable...
Burble...perhaps it is a question of "deep pockets" from BioNtec and Moderna "paying" for publicity !
Interesting that despite the presentation from SCLP, there is no mention of them in that article.
I sometimes wonder whether the delivery of our data isn’t as exciting. I appreciate our trials are earlier stage, but we never show data or scans from patients who were on the Ph1 trials (though I realise that was when we were trying electroporation), we occasionally show the swimmer plot, but it seems presenting data in the manner that we do, never seems to trigger that a-ha moment. Though I’m unsure what to suggest otherwise.
We had a fantastic opportunity here, sharing a session with some other strong players in this field, but it just seems to have fallen a bit flat.
Maybe that’s me becoming jaded by 14 years here. But I expected at least a minor up tick after all the presentations etc we’ve been doing recently
EE, "The exit route here is a corporate deal, at some point in the next year or so, on the back of trial results and proof of platforms….."
Indeed...or as bugs bunny would say ...that's it folks !!
Let's get those deals done ✔️
The exit route here is a corporate deal, at some point in the next year or so, on the back of trial results and proof of platforms…..
I imagine the main reason for delisting being brought up is because finances are steady, and trials are properly established and looking favourable. While anything is a possibility, delisting wasn't mentioned even during the financially very tight times and a trial drought. There will be a few who probably wish they'd thought of stirring the pot with this new bête noir to assist with a bit of trading leverage.
Honestly I don't see Scancell delisting anytime soon. Simply because they're too focused on getting the research across the line to worry about the stockmarket. Whilst this isn't great for investor updates, it's great for pushing their progress forward.
I've always thought of Scancell as a bunch of scientists who occasionally remember they're a public company and then instantly forget again and go back to the lab! To be fair, this is such an important piece of research they're working on, I'd rather it was that way round.
I believe the company will stay public and a buyout will be coming when the research is sufficiently de-risked. Could be Q4 or Q1 2025, who knows. But it will land with a bang.
Https://www.cancertherapyadvisor.com/reports/scib1-vaccine-nivo-ipi-melanoma/
Follow up from AACR.
As also mentioned by marcusl2.
Thanks all for the insight on this. Ive noted over the last 18 months or so that several LSE stocks have highlighted their low valuations.
Question regarding institutional investor divestments: These have curtained momentum on share price rises every time over the past few years. What options does Scancell (besides delisting)?
The neoadjuvant arm of the Modi-1 trial opened at the end on July 2023. I would hope that we get some result from this before the end of 2024. This is also the arm of the trial that Lindy said was most important to big pharma, as it would prove tha t Modi-1 works in the way they say it does.
I think any mention of possible update of the ModiFy data has been couched 'in 2024'.
The fact that we are told there will be a 'Clinical Update' of Modi-1, I would not be happy if that update is what we already know from April 2023. That would amount to a deliberate policy to reduce the share price by continuing to disappoint the market and thier shareholders.
Why offer any mention of Modi-1 if it is not a Clinical Update. I therefore propose that it is...
For a modi1 update, I think this news item is the latest indication of when we will be updated.
https://www.lse.co.uk/rns/SCLP/results-for-the-year-ended-30-april-2023-an9qb34t5po41pn.html
"Modi-1 (ModiFY trial)
· Modi-1 has completed dose escalation and safety cohorts of the Phase 1/2 ModiFY trial and is now into expansion cohorts
· Early data from patients receiving Modi-1 as a monotherapy showed good safety and tolerability, with no dose limiting toxicities observed in dose escalation cohorts
· Modi-1 demonstrated encouraging early efficacy in a head and neck cancer patient and in other hard- to-treat cancers such as high grade serous ovarian carcinoma (HGSOC) and triple negative breast cancer (TNBC)
· Early clinical data with Modi-1 expected to be available in 2024"
It's deliberately vague since Scancell do not know how fast Modi1 recruitment will be in the expansion cohorts. Not a promise, in other words.
And they wonder why the share price is derisory!
Honestly comms needs to be a lot better to keep investors updated.
Appreciate they're busy working on the research but investor relations have always been sub par. Was hoping the new appointees would rectify this but starting to have some doubts. Key opportunities missed.
I say this as a LTH. What they are doing is excellent work but they need to be more open and consistent with their investors.
Hiya Ray
My interest in the London conference is that the description for Scancell’s presentation is “Clinical Update” for both SCIB1 and Modi-1. The last meaningful data we had in Modi-1 was back in February 2023.
Entitled : Encouraging early efficacy data from monotherapy part of ModiFY Phase 1/2 clinical trial.
Now it’s not the Modi-1 +CPi cohort but surely it cannot be ‘here’s some data from over 12 months ago” Can It ?
I dam well hope not because as a shareholder I would be furious.
Thanks Bermuda,
I think the inability to hold in an ISA would be a major factor in deciding whether to hold or sell up.
Chester
I think we just resign ourselves to having data in Q3 for SCIB1 and Q4 for iSCIB1+ with the possibility of further slippage.
I personally don't have a problem with this and will consider topping up on SP weakness.
Remember the statisticians say 90% chance of achieving the 70% response rate. I would guess that Lindy consulted mathematician ex-colleagues at Nottingham UNI to arrive at this figure.
Thankyou Bermudashorts
For this post I have C4X disappointment and not sure what to do.
Have some in ISA as well I guess they will have to transfer out to ordinary acc .
Looks even cheaper today but the 3.9% decline has a 3.1% spread.
We only need to wait a week or so and we can get straight back on the ‘ what if’s and maybe’s ‘.
Immune-Oncology Summit Europe.
London 23rd to 25th
Clinical Updates on SCIB 1 and Modi 1.
Could be another possible maybe !!
Guessing when the SP positive Data will land is not for the faint hearted 🫣
Ruck,
Sorry have only just seen your 12.07. As square10 has said retail investors have a choice - either sell at the best price they can get or keep holding. Both Redx and C4X are putting in place a matched bargain facility run by JP Jenkins in order to help investors buy/sell after delisting. Essentially you let them know how many shares and the price and they'll try to match the trade for you. However you can't deal directly with them, it has to be via your broker and there is no guarantee the facility will remain in place in the long run.
If Scancell were to go down this route there would be a third option and that would be simply to vote against the delisting.